Two cases of uneventful pregnancies following the treatment of choriocarcinoma

Introduction. Gestational trophoblastic disease represents a distinguished group of disorders that are derived from placental trophoblastic tissue aroused from abnormal fertilization. Choriocarcinoma is a malignant human chorionic gonadotropin-producing epithelial tumor arising from villous trophoblast. The choice of the chemotherapy regime is based on the International Federation of Gynecology and Obstetrics stage and World Health Organisation score of the disease. The aim of this article is to show that successful pregnancy is possible even after treatment of high-risk gestational trophoblastic neoplasia. Outlines of cases. We present two successfully treated patients who achieved pregnancy and delivered healthy babies in term. Conclusion. Gestational trophoblastic neoplasia has become the most curable malignant disease since the introduction of chemotherapy, which is effective and well-tolerated, and allows fertility preservation in high-proportion of women.

[1]  R. Berkowitz,et al.  Diagnosis and management of gestational trophoblastic disease: 2021 update , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[2]  S. Sun,et al.  Gestational trophoblastic neoplasia: Novelties and challenges. , 2021, Placenta.

[3]  M. Seckl,et al.  Fertility and pregnancy outcome in gestational trophoblastic disease , 2021, International Journal of Gynecological Cancer.

[4]  Junjun Yang,et al.  Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ≥ 5 , 2021 .

[5]  M. Seckl,et al.  Treatment of gestational trophoblastic disease in the 2020s. , 2020, Current opinion in obstetrics & gynecology.

[6]  J. Tidy,et al.  Placental site trophoblastic tumour and epithelioid trophoblastic tumour. , 2020, Best practice & research. Clinical obstetrics & gynaecology.

[7]  H. Ngan,et al.  Surgery including fertility-sparing treatment of GTD , 2020, Best Practice & Research Clinical Obstetrics & Gynaecology.

[8]  M. Seckl,et al.  Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. , 2020, European journal of cancer.

[9]  D. Maucort-Boulch,et al.  Successful pregnancy in a cancer patient previously cured of a gestational trophoblastic tumor by immunotherapy. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. De Felici,et al.  Ovarian damage from chemotherapy and current approaches to its protection , 2019, Human reproduction update.

[11]  N. Sebire,et al.  When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients. , 2019, Gynecologic oncology.

[12]  H. Wand,et al.  Reproductive outcomes following treatment for a gynecological cancer diagnosis: a systematic review , 2019, Journal of Cancer Survivorship.

[13]  A. Gadducci,et al.  Reproductive Outcomes After Gestational Trophoblastic Neoplasia. A Comparison Between Single-Agent and Multiagent Chemotherapy: Retrospective Analysis From the MITO-9 Group , 2017, International Journal of Gynecologic Cancer.

[14]  A. Iwase,et al.  Anti-Müllerian hormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[15]  N. Tanaka,et al.  Risk of abnormal pregnancy completing chemotherapy for gestational trophoblastic tumor. , 2003, Gynecologic oncology.